MRN specializes in the conduct of clinical trial visits in the patient’s home and supporting clinical trial sites with nursing resources. We believe in reducing the burden of participation on patients and reducing the burden on participation on sites – building more patient-centric clinical trials.
MRN offers two core services in the management of complex clinical trials:
Home Trial Support (HTS) is the conduct of clinical trial visits in the patient’s home. This replaces a number of protocol defined visits which would normally take place onsite, and relocates them in the patient’s home – reducing the burden of the trial on the patient and significantly boosting patient recruitment and maximizing patient retention. With HTS, sites can recruit patients from a wider geographical region and reach a larger patient pool, as well as increase their consenting and retention rates. We have seen that reducing the burden on patients directly increases recruitment by 60% or more and typically maintains patient retention at over 95%, as well as reducing the burden on clinical sites.
Site Nurse Support (SNS) places experienced research nurses into sites to manage trials; this enables each site to focus on patient identification and selection, as well as facilitating performance of all procedures in a timely manner. Placements can be made at single sites, or nursing teams can be pulled together to support sites across whole countries or trials. With SNS, sites have a dedicated resource to identify and screen patients from the increased patient pool effectively.
Together, the impact of these services can result in an increase of up to 600% of completed patients per site.
MRN is a recognized leader in the Home Trial Support clinical trials field. We have a geographical coverage of over 40 countries where we can provide our services. Headquartered in the UK and with offices in North America and Spain, our Vendor Contracts and Management Team (VCMT) have enabled us to conduct Home Trial support visits across all major clinical research countries spanning North America, Europe, Asia and Australasia
Whether your priority is networking with sponsors and CRO attendees or learning best practices built for research sites, the Summit will provide a unique experience for your business.
For the last 16 years, the Global Site Solutions Summit has been committed to being “the site’s meeting.” The Summit provides a unique hub where sites, sponsors, CRO executives and regulators come together and share best practices, build their businesses, and develop new partnerships through debates, ideation sessions, workshops and focus groups.
SCRS is confident that by increasing site sustainability, all life science stakeholders will realize greater efficiency and profitability, and successfully meet our ultimate commitment to bring safe medical treatments to patients faster. The Global Summit will deliver the high-quality education, training, and best practices that attendees have come to expect.
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 82,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
